Welcome to LookChem.com Sign In|Join Free

CAS

  • or

37526-85-5

Post Buying Request

37526-85-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

37526-85-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 37526-85-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,5,2 and 6 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 37526-85:
(7*3)+(6*7)+(5*5)+(4*2)+(3*6)+(2*8)+(1*5)=135
135 % 10 = 5
So 37526-85-5 is a valid CAS Registry Number.

37526-85-5Relevant articles and documents

A concise and flexible synthesis of the core structure of pinnaic acid

Yang, Sung-Hyun,Caprio, Vittorio

, p. 1219 - 1222 (2007)

An efficient and flexible approach to the core structure of pinnaic acid has been developed that centres on the microwave-induced 1,3-dipolar cycloaddition of a novel spirocyclic nitrone 5 with alkene 7. The application of this nitrone to the synthesis of a diverse set of C5-substituted analogues of pinnaic acid is also demonstrated. Georg Thieme Verlag Stuttgart.

Cobalt-Bisoxazoline-Catalyzed Enantioselective Cross-Coupling of α-Bromo Esters with Alkenyl Grignard Reagents

Zhou, Yun,Wang, Lifeng,Yuan, Gucheng,Liu, Shikuo,Sun, Xiao,Yuan, Chaonan,Yang, Yuxiong,Bian, Qinghua,Wang, Min,Zhong, Jiangchun

supporting information, p. 4532 - 4536 (2020/06/05)

The first catalytic asymmetric Kumada cross-coupling of organic halides with alkenyl Grignard reagents has been developed. The reaction was promoted by the cobalt-bisoxazoline catalyst and afforded various α-alkyl-β,γ-unsaturated esters with excellent enantioselectivities and moderate to good yields (≤95% ee and ≤82% yields). The formal synthesis of the California red scale pheromone using this method was investigated, and radical clock experiments were performed.

CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS

-

Paragraph 00314, (2013/03/26)

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 37526-85-5